RxDoctor Payments Data

Ephraim Weiss, MD

Interventional Cardiology · Mesa, AZNPI 1801186952

Payments from drug & device makers

$584in general payments, 2019–2025

Across 17 payments — averaging $34.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bard Peripheral Vascular, Inc.$204
  • AstraZeneca$126
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$55
  • Abiomed$47
  • Abbott$38
  • Atricure, Inc.$38
  • plus $76 from 4 others

What the payments were for

  • Food & beverage$584100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$584 in reported general payments places this provider in the 5th percentile of 223 interventional cardiology providers in Arizona.

See all interventional cardiology providers in Arizona

Medicare billing

Part B allowed, 2024
$671,909
Medicare patients
1,705
Services billed
5,814

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban507$684,380
XareltoRivaroxaban101$122,296
Repatha SureclickEvolocumab118$101,875
EntrestoSacubitril/Valsartan57$78,653
BrilintaTicagrelor29$27,222
FarxigaDapagliflozin Propanediol23$21,311
Praluent PenAlirocumab21$15,965
Atorvastatin Calcium808$7,026
Metoprolol Succinate510$6,220
ClopidogrelClopidogrel Bisulfate368$3,576
Ezetimibe131$3,186
Rosuvastatin Calcium242$3,083
Bumetanide77$2,989
Losartan Potassium274$2,967
Lisinopril438$2,533

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBrilinta, Farxiga$126$48,53352 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 5th percentile of 223 interventional cardiology providers in Arizona.

Other interventional cardiology in Mesa

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →